Zhixiang Jintai (688443.SH): GR1802 injection starts Phase III clinical trial for allergic rhinitis.

Zhitong Financial News App, Zhixiang Jintai (688443.SH) announced that recently, the company has officially started the Phase III clinical trial of the evaluation of the effectiveness and safety of GR1802 injection combined with background therapy in patients with seasonal allergic rhinitis in a randomized, double-blind, placebo-controlled, multicenter study, after completing the communication meeting with the Center for Drug Evaluation (CDE) of the National Medical Products Administration on the EOP2 (the end of Phase II clinical trial/ before the start of Phase III clinical trial).